Literature DB >> 33522936

Building a trusted framework for uncertainty assessment in rare diseases: suggestions for improvement (Response to "TRUST4RD: tool for reducing uncertainties in the evidence generation for specialised treatments for rare diseases").

Sabine E Grimm1, Xavier Pouwels2, Bram L T Ramaekers3, Ben Wijnen3, Saskia Knies4, Janneke Grutters5, Manuela A Joore3.   

Abstract

The aim of this letter to the editor is to provide a comprehensive summary of uncertainty assessment in Health Technology Assessment, with a focus on transferability to the setting of rare diseases. The authors of "TRUST4RD: tool for reducing uncertainties in the evidence generation for specialised treatments for rare diseases" presented recommendations for reducing uncertainty in rare diseases. Their article is of great importance but unfortunately suffers from a lack of references to the wider uncertainty in Health Technology Assessment and research prioritisation literature and consequently fails to provide a trusted framework for decision-making in rare diseases. In this letter to the editor we critique the authors' tool and provide pointers as to how their proposal can be strengthened. We present references to the literature, including our own tool for uncertainty assessment (TRUST; unrelated to the authors' research), apply TRUST to two assessments of orphan drugs in rare diseases and provide a broader perspective on uncertainty and risk management in rare diseases, including a detailed research agenda.

Entities:  

Keywords:  Health economics; Health technology assessment; Orphan diseases; Uncertainty

Mesh:

Year:  2021        PMID: 33522936      PMCID: PMC7849113          DOI: 10.1186/s13023-020-01666-4

Source DB:  PubMed          Journal:  Orphanet J Rare Dis        ISSN: 1750-1172            Impact factor:   4.123


  23 in total

1.  Expected value of information and decision making in HTA.

Authors:  Simon Eckermann; Andrew R Willan
Journal:  Health Econ       Date:  2007-02       Impact factor: 3.046

2.  A rational framework for decision making by the National Institute For Clinical Excellence (NICE).

Authors:  Karl Claxton; Mark Sculpher; Michael Drummond
Journal:  Lancet       Date:  2002-08-31       Impact factor: 79.321

Review 3.  Characterizing structural uncertainty in decision analytic models: a review and application of methods.

Authors:  Laura Bojke; Karl Claxton; Mark Sculpher; Stephen Palmer
Journal:  Value Health       Date:  2009 Jul-Aug       Impact factor: 5.725

4.  Evidence-based decision making: when should we wait for more information?

Authors:  Kalipso Chalkidou; Joanne Lord; Alastair Fischer; Peter Littlejohns
Journal:  Health Aff (Millwood)       Date:  2008 Nov-Dec       Impact factor: 6.301

Review 5.  A Review of Methods for Analysis of the Expected Value of Information.

Authors:  Anna Heath; Ioanna Manolopoulou; Gianluca Baio
Journal:  Med Decis Making       Date:  2017-04-14       Impact factor: 2.583

6.  Model parameter estimation and uncertainty analysis: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force Working Group-6.

Authors:  Andrew H Briggs; Milton C Weinstein; Elisabeth A L Fenwick; Jonathan Karnon; Mark J Sculpher; A David Paltiel
Journal:  Med Decis Making       Date:  2012 Sep-Oct       Impact factor: 2.583

7.  Calculating the Expected Value of Sample Information in Practice: Considerations from 3 Case Studies.

Authors:  Anna Heath; Natalia Kunst; Christopher Jackson; Mark Strong; Fernando Alarid-Escudero; Jeremy D Goldhaber-Fiebert; Gianluca Baio; Nicolas A Menzies; Hawre Jalal
Journal:  Med Decis Making       Date:  2020-04-16       Impact factor: 2.583

8.  Value of Information Analytical Methods: Report 2 of the ISPOR Value of Information Analysis Emerging Good Practices Task Force.

Authors:  Claire Rothery; Mark Strong; Hendrik Erik Koffijberg; Anirban Basu; Salah Ghabri; Saskia Knies; James F Murray; Gillian D Sanders Schmidler; Lotte Steuten; Elisabeth Fenwick
Journal:  Value Health       Date:  2020-03       Impact factor: 5.725

9.  The HTA Risk Analysis Chart: Visualising the Need for and Potential Value of Managed Entry Agreements in Health Technology Assessment.

Authors:  Sabine Elisabeth Grimm; Mark Strong; Alan Brennan; Allan J Wailoo
Journal:  Pharmacoeconomics       Date:  2017-12       Impact factor: 4.981

10.  Computing the Expected Value of Sample Information Efficiently: Practical Guidance and Recommendations for Four Model-Based Methods.

Authors:  Natalia Kunst; Edward C F Wilson; David Glynn; Fernando Alarid-Escudero; Gianluca Baio; Alan Brennan; Michael Fairley; Jeremy D Goldhaber-Fiebert; Chris Jackson; Hawre Jalal; Nicolas A Menzies; Mark Strong; Howard Thom; Anna Heath
Journal:  Value Health       Date:  2020-05-27       Impact factor: 5.725

View more
  1 in total

1.  Correction to: Building a trusted framework for uncertainty assessment in rare diseases: suggestions for improvement (Response to "TRUST4RD: tool for reducing uncertainties in the evidence generation for specialised treatments for rare diseases").

Authors:  Sabine E Grimm; Xavier Pouwels; Bram L T Ramaekers; Ben Wijnen; Saskia Knies; Janneke Grutters; Manuela A Joore
Journal:  Orphanet J Rare Dis       Date:  2021-07-19       Impact factor: 4.123

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.